Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma

Giovanni Melioli, Giovanni Margarino, Marco Scala, Paola Mereu, Sergio Bertoglio, Guido Schenone, Maurizio Barbaresi, Anna Maria Machi, Leonardo Santi, Fausto Badellino, Lorenzo Moretta

Research output: Contribution to journalArticle

Abstract

Patients with advanced head and neck squamous cell carcinoma (HNSCC) are severely immunocompromised. In virtually all such patients who have been studied, reduced numbers of circulating CD3+ T-cell-receptor (TCR)a/p+ T lymphocytes, a reduction of natural killer (NK) activity, and a poor induction of lymphokine-activated killer (LAK) cell activity (following in vitro treatment with recombinant interleukin-2 [rIL-2]) have been detected. Recently, however, it has been demonstrated that perilymphatic injections of low doses of rIL-2 may induce a local reduction of tumor masses in these patients. The present study, a cooperative pilot effort on the clinical effects of this route of administration, showed an activation of the lytic machinery in lymphocytes belonging to the T-cell lineage, as well as a potentiation of NK activity in the peripheral blood. These findings demonstrated that the severe immunodeficiency of HNSCC patients may be at least partially corrected by in vivo administration of rIL-2.\

Original languageEnglish
Pages (from-to)572-578
Number of pages7
JournalLaryngoscope
Volume102
Issue number5
Publication statusPublished - 1992

    Fingerprint

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Melioli, G., Margarino, G., Scala, M., Mereu, P., Bertoglio, S., Schenone, G., Barbaresi, M., Maria Machi, A., Santi, L., Badellino, F., & Moretta, L. (1992). Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma. Laryngoscope, 102(5), 572-578.